TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7050369

Group type: EXPERIMENTAL
Intervention: Exercise group (supervised exercise course, twice weekly for three months)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Exercise group (for those with inferior MI)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (for those with inferior MI)
Number of subjects: 303
Study: 31641007

Group type: EXPERIMENTAL
Intervention: OncoMasTR Molecular Score (OMm)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: OncoMasTR Risk Score (OMclin2)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: OncoMasTR Clinical Score (OMclin1)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Oncotype DX Recurrence Score (RS)
Number of subjects: 646
Study: 30826759

Group type: EXPERIMENTAL
Intervention: Text message support programme (5 messages per week for 26 weeks)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 310
Study: 27104841

Group type: EXPERIMENTAL
Intervention: Low-frequency stimulation (LFS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: High-frequency stimulation (HFS)
Number of subjects: 19
Study: 26718299

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% Achyranthes aspera mouthwash
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15% Punica granatum mouthwash
Number of subjects: 60
Study: 22932777

Group type: EXPERIMENTAL
Intervention: Concentrated DHA fish oil (n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 36
Study: 21617138

Group type: EXPERIMENTAL
Intervention: 1 g/day n-3 PUFA
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 19331721

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) once daily for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 31
Study: 16476878

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE), 0.625 mg/d
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study: 14761878

Group type: EXPERIMENTAL
Intervention: HIGH-CHO (10 g/kg body mass CHO)
Number of subjects: 7

Group type: COMPARATOR
Intervention: LOW-CHO (0.7 g/kg body mass CHO)
Number of subjects: 7
Study: 11738460

Group type: EXPERIMENTAL
Intervention: Problem‐Solving Treatment
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 430
Study: 9389286

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol spray (110 microg in each nostril once daily)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Fluticasone propionate aqueous solution spray (100 microg in each nostril once daily)
Number of subjects: 233
Study: 7930715

Group type: COMPARATOR
Intervention: Low-risk HPV probes
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low- and high-risk HPV probes
Number of subjects: 62
Study: 3129588

Group type: EXPERIMENTAL
Intervention: Double-lumen catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-lumen catheter (bilateral)
Number of subjects: 0
Study: 31144609

Group type: EXPERIMENTAL
Intervention: High-intensity lower extremity exercise
Number of subjects: 13

Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 13
Study: 28334510

Group type: EXPERIMENTAL
Intervention: Testosterone cream (12.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone cream (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone cream (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone cream (all doses)
Number of subjects: 0
Study: 25726918

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Closed method of treatment
Number of subjects: 50
Study: 23224764

Group type: EXPERIMENTAL
Intervention: BLM-240 with 50-70% N2O in O2
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: BLM-240 with 30% O2 in air
Number of subjects: 216

Group type: COMPARATOR
Intervention: Sevoflurane with 50-70% N2O in O2
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: BLM-240 (both groups)
Number of subjects: 216
Study: 21144724

Group type: EXPERIMENTAL
Intervention: NVA237 50 μg once daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 18180343

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (three-dose regimen)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (four-dose regimen)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 98
Study: 16439495

Group type: EXPERIMENTAL
Intervention: Daily activity recording for 6 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 12562827

Group type: EXPERIMENTAL
Intervention: Controlled ethanol intake study
Number of subjects: 0
Study: 10712354

Group type: COMPARATOR
Intervention: 400 microg of budesonide plus placebo, twice daily (BUD800)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 microg of budesonide plus 12 microg of formoterol, twice daily (BUD200+F)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BUD200+F and BUD800
Number of subjects: 60
Study: 9088812

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 70
Study: 8454839

Group type: EXPERIMENTAL
Intervention: Readables progressive‐addition lenses
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional spherical spectacle lenses
Number of subjects: 36
Study: 3739595

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (dosage ratio 2:1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 30
Study: 30482633

Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 therapy
Number of subjects: 75
Study: 27168434

Group type: EXPERIMENTAL
Intervention: Normal pattern of lung-function growth
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Reduced growth and early decline
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Reduced growth only
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Normal growth and early decline
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Lung-function impairment consistent with COPD
Number of subjects: 684
Study: 23864515

Group type: EXPERIMENTAL
Intervention: Traditional dancing (group A, n=18)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Formal exercise training (group B, n=16)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sedentary control group (group C, n=17)
Number of subjects: 51
Study: 21870192

Group type: EXPERIMENTAL
Intervention: Choice-based conjoint analysis
Number of subjects: 104

Group type: COMPARATOR
Intervention: Rating and ranking task
Number of subjects: 104
Study: 20022572

Group type: EXPERIMENTAL
Intervention: Rasburicase (0.2mg/kg/day, once daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Allopurinol (10mg/kg/day every 8h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 32

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 32
Study: 18508321

Group type: EXPERIMENTAL
Intervention: Lenograstim 7.5 microg/kg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Filgrastim 10 microg/kg/day
Number of subjects: 40
Study: 15809475

Group type: EXPERIMENTAL
Intervention: 11C-DAG accumulation in post-MI patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Correlation of 11C-DAG accumulation with LV end-diastolic volume index
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Correlation of 11C-DAG accumulation with plasma concentration of brain natriuretic peptide
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Correlation of 11C-DAG accumulation with LV ejection fraction
Number of subjects: 17
Study: 14652472

Group type: EXPERIMENTAL
Intervention: Back-café group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Training group
Number of subjects: 90
Study: 10086255

Group type: EXPERIMENTAL
Intervention: Family practice return visits
Number of subjects: 509

Group type: COMPARATOR
Intervention: Internal medicine return visits
Number of subjects: 509
Study: 9101941

Group type: EXPERIMENTAL
Intervention: Holmium and Nd:YAG laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hook electrode (control)
Number of subjects: 0
Study: 8517437

Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3125788

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 800 mg oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 100 mg intravenous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg oral dose with 1,000 mg probenecid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin multiple dosing of 800 or 1,200 mg once a day over 10 days
Number of subjects: 0
Study: 28992314

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Free diet (FD)
Number of subjects: 60
Study: 27630014

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (1,200 mg eicosapentaenoic acid and 600 mg docosahexaenoic acid daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs
Number of subjects: 112
Study: 26228967

Group type: EXPERIMENTAL
Intervention: Atropine 1%
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo eyedrops (Control)
Number of subjects: 132
Study: 23706353

Group type: EXPERIMENTAL
Intervention: Nutrition coaching (8 sessions over 6 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (baseline only)
Number of subjects: 50
Study: 20526388

Group type: EXPERIMENTAL
Intervention: Generic clopidogrel bisulfate (Plavitor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Original clopidogrel bisulfate (Plavix)
Number of subjects: 20
Study: 18506608

Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (patients without AF)
Number of subjects: 98
Study: 16804391

Group type: EXPERIMENTAL
Intervention: Positive biological predictive score (C-reactive protein >20 mg/L and erythrocyte sedimentation rate >15 mm)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Negative biological predictive score (both markers lower than limits)
Number of subjects: 71
Study: 12792351

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) replacing d4T (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) replacing PI or NNRTI (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) plus AZT replacing d4T and PI or NNRTI (group 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (d4T with PI or NNRTI)
Number of subjects: 30
Study: 10334517

Group type: EXPERIMENTAL
Intervention: 5‐FU infusion and bolus CF with standard whole pelvic RT
Number of subjects: 368

Group type: COMPARATOR
Intervention: Oral HU with standard whole pelvic RT
Number of subjects: 368
Study: 7710725

Group type: EXPERIMENTAL
Intervention: Regular exercise (group 1a)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nonregular exercise (group 1b)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 146
Study: 2667385

Group type: EXPERIMENTAL
Intervention: PTFE-silicone graft
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional PTFE grafts
Number of subjects: 30
Study: 414287

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31914880

Group type: EXPERIMENTAL
Intervention: Genetically predicted Atrial Fibrillation (AF)
Number of subjects: 1030836

Group type: EXPERIMENTAL
Intervention: Mendelian randomization-Egger
Number of subjects: 1030836
Study: 31219252

Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Traditional Training (TT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Stretching Group (SG)
Number of subjects: 52
Study: 28493642

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 152

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 152
Study: 25088308

Group type: EXPERIMENTAL
Intervention: Physiotherapy triage assessment
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 208
Study: 23983725

Group type: EXPERIMENTAL
Intervention: Breastfeeding during vaccination
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray before vaccination
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 144
Study: 21565328

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) with interoceptive exposure (IE) to visceral sensations
Number of subjects: 110

Group type: COMPARATOR
Intervention: Stress management (SM)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 110
Study: 20009494

Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 118

Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 118
Study: 16229053

Group type: EXPERIMENTAL
Intervention: Accurate information about cervical cancer screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective information on an improvement to the screening programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: No information provided
Number of subjects: 0
Study: 15554982

Group type: EXPERIMENTAL
Intervention: Propofol administered by anesthetists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol administered by registered nurses
Number of subjects: 0
Study: 11529850

Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation (PSCT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 204
Study: 9434700

Group type: EXPERIMENTAL
Intervention: Group PN (19 patients) received glucose and crystalloid amino acid solution at a dosage of 0.8 +/- 0.1 gm/kg per day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Group STANDARD (18 patients) received glucose as the maintenance fluid
Number of subjects: 37

Group type: COMPARATOR
Intervention: Group STANDARD
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Group PN
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 37
Study: 7880661

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg i.m. injection 1-2 h before operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac 75 mg i.m. immediately after surgery
Number of subjects: 40
Study: 3069749

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 29139320

Group type: EXPERIMENTAL
Intervention: Cable news watching (Fox News and MSNBC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Negative control (Public Broadcasting Station)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Positive control (Trier social stress test)
Number of subjects: 34
Study: 28263765

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (50mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: COMPARATOR
Intervention: Comparison between testosterone and placebo groups
Number of subjects: 82
Study: 26161483

Group type: EXPERIMENTAL
Intervention: Community-based blood pressure monitor (CBPM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Validated automatic blood pressure monitor (ABPM)
Number of subjects: 50
Study: 23637214

Group type: EXPERIMENTAL
Intervention: Volume-rendered images derived from intraoperative cone-beam computed tomography imaging
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional fluoroscopic C-arm
Number of subjects: 24
Study: 22942521

Group type: EXPERIMENTAL
Intervention: Extended-role practitioners
Number of subjects: 58

Group type: COMPARATOR
Intervention: Experienced therapists
Number of subjects: 58
Study: 18469247

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (5 mg/kg) with high glycemic index meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (5 mg/kg) with low glycemic index meal
Number of subjects: 10
Study: 16520564

Group type: EXPERIMENTAL
Intervention: Deep breathing exercises with Incentive Spirometer
Number of subjects: 34

Group type: COMPARATOR
Intervention: Deep breathing exercise without Incentive Spirometer
Number of subjects: 34
Study: 12853868

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Perceived health functioning
Number of subjects: 199
Study: 10812390

Group type: EXPERIMENTAL
Intervention: Smectite (2 x 6 g daily)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (2 x 6 g daily)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Smectite (2 x 6 g daily) in subgroup with small bowel volume <= 837.5 ml
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo in subgroup with small bowel volume <= 837.5 ml
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Smectite (2 x 6 g daily) in subgroup with small bowel volume > 837.5 ml
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo in subgroup with small bowel volume > 837.5 ml
Number of subjects: 176
Study: 8984754

Group type: EXPERIMENTAL
Intervention: Operation and walking-cast
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Walking-cast alone
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Elastic bandage
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 79
Study: 1452528

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 25
Study: 6137021

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every 6 h) with alprazolam (1.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every 6 h) with triazolam (0.5 mg)
Number of subjects: 0
Study: 30823878

Group type: EXPERIMENTAL
Intervention: Teaching Basic Life Support (case group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no teaching)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Training of community health professionals
Number of subjects: 92
Study: 29983350

Group type: EXPERIMENTAL
Intervention: 40 mg adalimumab
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26780167

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy
Number of subjects: 200
Study: 24429400

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 112
Study: 21812672

Group type: EXPERIMENTAL
Intervention: Horse ATG
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rabbit ATG
Number of subjects: 120
Study: 19702711

Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone acetonide (ivTA)
Number of subjects: 107

Group type: COMPARATOR
Intervention: 4 mg triamcinolone alone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 4 mg triamcinolone plus sequential laser
Number of subjects: 107
Study: 16749588

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg/day (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg/day and potassium citrate 20 mlEq/day (Group C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 150
Study: 15310446

Group type: EXPERIMENTAL
Intervention: Lumbar epidural blockade with bupivacaine 0.25% (10 mg bolus and 5 mg/h continuous infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Customary antihypertensive treatment
Number of subjects: 24
Study: 11181756

Group type: EXPERIMENTAL
Intervention: LIPC promoter polymorphism
Number of subjects: 578
Study: 9709283

Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 3
Study: 7690729

Group type: EXPERIMENTAL
Intervention: Modified Magara technique
Number of subjects: 84

Group type: COMPARATOR
Intervention: Meigs technique
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 84
Study: 2424239

Group type: EXPERIMENTAL
Intervention: Arotinoid Ro 13‐6298
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etretin
Number of subjects: 30
Study: 1100294

Group type: EXPERIMENTAL
Intervention: Lirutrin (measles‐mumps‐rubella live, attenuated virus vaccine)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 31399456

Group type: EXPERIMENTAL
Intervention: Group-based multicomponent intervention combined with individualised clinical facilitator led support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help booklet and relaxation compact disc
Number of subjects: 0
Study: 28295912

Group type: EXPERIMENTAL
Intervention: Robotic exercise (balance exercise assist robot)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 27
Study: 25394681

Group type: EXPERIMENTAL
Intervention: BCAA and zinc-enriched supplementation (6,400 mg/day BCAAs and 10 mg/day zinc)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: BCAA and zinc-enriched supplementation
Number of subjects: 53